GGrantIndex
← Leaderboards

Elliott D Crouser

Ohio State University

Google Scholar ↗PubMed ↗ORCID ↗
$4,838,276
Attributed
$7,433,413
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,433,413 · 11

By mechanism

R01$2,384,181 · 1
R21$1,935,979 · 5
U01$1,614,003 · 1
R34$708,762 · 1
K08$632,745 · 1
R03$147,743 · 1

Top collaborators

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Lung”

Research focus

LungUnited States National Institutes Of HealthCellsClinical TrialsSarcoidosisInflammationGranulomatousBiological MarkersAffectLinkInvestigationResponseTissuesPulmonary SarcoidosisAttenuatedUniversitiesMissionImmuneDesignGranulomaDisabilityInnovationCharacteristicsPathway Interactions

Grant awards (27)

Molecular Characterization of Progressive Pulmonary Sarcoidosis$784,774
R01 · FY2025 · HL
Redox Regulation of Sarcoidosis Granulomas and Fibrosis$236,250
R21 · FY2025 · AI · contact PI
Molecular Characterization of Progressive Pulmonary Sarcoidosis$772,729
R01 · FY2024 · HL
Supplemental Citicoline Administration for Reduction of Lung Injury Efficacy Trial (SCARLET)$494,210
U01 · FY2024 · AI · contact PI
Role of Renin-Angiotensin-Aldosterone System during sarcoidosis granuloma formation$236,250
R21 · FY2024 · AI · contact PI
Redox Regulation of Sarcoidosis Granulomas and Fibrosis$196,875
R21 · FY2024 · AI · contact PI
Molecular Characterization of Progressive Pulmonary Sarcoidosis$826,678
R01 · FY2023 · HL
Supplemental Citicoline Administration for Reduction of Lung Injury Efficacy Trial (SCARLET)$543,218
U01 · FY2023 · AI · contact PI
Role of Renin-Angiotensin-Aldosterone System during sarcoidosis granuloma formation$196,875
R21 · FY2023 · AI · contact PI
Supplemental Citicoline Administration for Reduction of Lung Injury Efficacy Trial (SCARLET)$576,575
U01 · FY2022 · AI · contact PI
Circulating Exosome microRNA as Markers of Severe Sarcoidosis Phenotypes$123,476
R21 · FY2018 · HL · contact PI
Circulating Exosome microRNA as Markers of Severe Sarcoidosis Phenotypes$122,628
R21 · FY2017 · HL · contact PI
Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study$232,908
R34 · FY2016 · HL · contact PI
Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study$229,387
R34 · FY2015 · HL · contact PI
Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study$246,467
R34 · FY2014 · HL · contact PI
Sarcoidosis Health Care Disparities and Clinical Research Challenges$10,000
R13 · FY2014 · HL · contact PI
Dendritic Cell Activation by Mitochondrial Transcription Factor A$225,000
R21 · FY2010 · AI · contact PI
Dendritic Cell Activation by Mitochondrial Transcription Factor A$187,500
R21 · FY2009 · AI · contact PI
Induction of Inflammation by Mitochondrial Proteins$72,993
R03 · FY2006 · AI · contact PI
Stromal Gene Expression During Pulmonary Sarcoidosis$224,250
R21 · FY2005 · HL
Induction of Inflammation by Mitochondrial Proteins$74,750
R03 · FY2005 · AI
Stromal Gene Expression During Pulmonary Sarcoidosis$186,875
R21 · FY2004 · HL
MITOCHONDRIAL CYTOCHROME C RELEASE VIA MEMBRANE PORES$126,549
K08 · FY2004 · HL
MITOCHONDRIAL CYTOCHROME C RELEASE VIA MEMBRANE PORES$126,549
K08 · FY2003 · HL
MITOCHONDRIAL CYTOCHROME C RELEASE VIA MEMBRANE PORES$126,549
K08 · FY2002 · HL
MITOCHONDRIAL CYTOCHROME C RELEASE VIA MEMBRANE PORES$126,549
K08 · FY2001 · HL
MITOCHONDRIAL CYTOCHROME C RELEASE VIA MEMBRANE PORES$126,549
K08 · FY2000 · HL